ALXO logo

ALXO
Alx Oncology Holdings Inc

1,248
Mkt Cap
$267.78M
Volume
997,472.00
52W High
$2.66
52W Low
$0.404
PE Ratio
-1.33
ALXO Fundamentals
Price
$2.00
Prev Close
$1.99
Open
$1.99
50D MA
$1.90
Beta
1.48
Avg. Volume
1.21M
EPS (Annual)
-$1.90
P/B
1.77
Rev/Employee
$0.00
$30.61
Loading...
Loading...
News
all
press releases
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
News Placeholder
More News
News Placeholder
ALX Oncology (ALXO) to Release Quarterly Earnings on Thursday
ALX Oncology (NASDAQ:ALXO) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-alx-oncology-holdings-inc-stock...
News Placeholder
ALX Oncology (NASDAQ:ALXO) Lowered to "Sell" Rating by Wall Street Zen
Wall Street Zen downgraded ALX Oncology from a "hold" rating to a "sell" rating in a research report on Saturday...
News Placeholder
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.
News Placeholder
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update
ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totaling...
News Placeholder
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by Brokerages
ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are currently covering the company, MarketBeat...
News Placeholder
ALX Oncology (NASDAQ:ALXO) CEO Sells $26,714.87 in Stock
ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) CEO Jason Lettmann sold 12,311 shares of the company's stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $2.17, for a total value of $26,714.87. Following the transaction, the chief...
News Placeholder
Insider Selling: ALX Oncology (NASDAQ:ALXO) CEO Sells 12,311 Shares of Stock
ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) CEO Jason Lettmann sold 12,311 shares of the firm's stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an...
News Placeholder
Wells Fargo & Company Begins Coverage on ALX Oncology (NASDAQ:ALXO)
Wells Fargo & Company initiated coverage on ALX Oncology in a research note on Thursday. They issued an "overweight" rating and a $5.00 target price for the company...
News Placeholder
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA
Aldeyra Therapeutics stock plunges 71% after the FDA issues a third CRL for the resubmitted reproxalap NDA for the treatment of dry eye disease.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available